Posthypoxic myoclonus (the Lance‐Adams syndrome) in the intensive care unit

Harper, S.; Wilkes, R. G.

doi:10.1111/j.1365-2044.1991.tb09409.x

Cited by 42 publications

(34 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myoclonus status epilepticus has been reported with patients surviving only with severe disability including persistent vegetative state. 7,20,56 Incidental cases have been described with good recovery, [57][58][59][60] mainly in patients in whom circulatory arrest was secondary to respiratory failure. In some of these cases, accumulation of sedative agents could have been confounders, and in others, myoclonus may not have been generalized, persistent, and merely sporadic.…”

mentioning

confidence: 99%

Practice Parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review) [RETIRED]

Wijdicks

Hijdra²,

Young³

et al. 2006

Neurology

1,151

872

View full text Add to dashboard Cite

Abstract-Objective:To systematically review outcomes in comatose survivors after cardiac arrest and cardiopulmonary resuscitation (CPR). Methods: The authors analyzed studies (1966 to 2006) that explored predictors of death or unconsciousness after 1 month or unconsciousness or severe disability after 6 months. Results: The authors identified four class I studies, three class II studies, and five class III studies on clinical findings and circumstances.

show abstract

mentioning

confidence: 99%

Practice Parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review) [RETIRED]

Wijdicks

Hijdra²,

Young³

et al. 2006

Neurology

1,151

872

View full text Add to dashboard Cite

show abstract

“…In addition to these clinical signs, a number of neurophysiological and laboratory tests, such as absence of cortical somatosensory evoked potential, CSF creatinine kinase and lactate have been identified as prognostic indicators[10,11,12]. Postanoxic myoclonus status epilepticus (MSE) is thought to reflect irreversible neocortical damage and has been considered a poor prognostic factor, but there have been reports of survivors [13,14,15]. We report a series of patients who developed MSE after anoxia.…”

Section: Introductionmentioning

confidence: 99%

Prognosis following Postanoxic Myoclonus Status epilepticus

et al. 2005

View full text Add to dashboard Cite

Prediction of outcome after cardiac arrest has important ethical and socioeconomic implications. In general, delay in recovery of neurological function is associated with a worse prognosis. The presence of myoclonic seizures early after anoxia has been identified as a poor prognostic factor. We report a series of patients who developed postanoxic myoclonus status epilepticus (MSE), which was defined as continuous myoclonic seizure activity lasting 30 min or more. The results from 18 patients were retrieved, 11 men and 7 women, age ranging from 29 to 90 years. Myoclonus developed a mean of 11.7 h after cardiac arrest, persisting for a mean of 60.5 h. Sixteen (89%) died following MSE and the 2 survivors were highly dependent or remained in a persistent vegetative state, supporting the view that prognosis is poor in this condition.

show abstract

“…In addition to myoclonus, their patients demonstrated dysmetria, intention tremor, dysarthria, and ataxia. However, the pathophysiology of posthypoxic action myoclonus (Lance-Adams syndrome) is poorly understood [14,15]. Electrophysiological investigation points to abnormal burst firing in neurons in the cortex, brainstem, or in both areas [14,15].…”

Section: Discussionmentioning

confidence: 98%

Trimethoprim-Sulfamethoxazole Exacerbates Posthypoxic Action Myoclonus in a Patient with Suspicion of Pneumocystis jiroveci Infection

et al. 2004

View full text Add to dashboard Cite

We describe a 58-year-old patient with relapsing high-grade non-Hodgkin's lymphoma who exhibited exacerbation of posthypoxic action myoclonus during high-dose intravenous trimethoprim-sulfamethoxazole (TMP-SMX) treatment for highly suspicious Pneumocystis jiroveci pneumonia (PCP). Three months previously the patient had experienced a hypoxic insult caused by respiratory arrest due to an anaphylactic reaction to antibiotic therapy. He had developed posthypoxic action myoclonus (Lance-Adams syndrome), which was well controlled by oral treatment with piracetam. However, after TMP-SMX therapy (115 mg/kg daily) was started for suspicion of newly developed PCP, posthypoxic action myoclonus worsened dramatically resulting in complete disability. Anti-myoclonic therapy with increased doses of piracetam and valproic acid did not significantly improve his clinical condition. Only when TMPSMX doses were reduced (38 mg/kg daily) on day 12 did action myoclonus cease within 2 to 3 days. We suggest that TMP-SMX can exacerbate posthypoxic action myoclonus.

show abstract

Posthypoxic myoclonus (the Lance‐Adams syndrome) in the intensive care unit

Abstract: SummaryThe

Cited by 42 publications

References 8 publications

Practice Parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review) [RETIRED]

Practice Parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review) [RETIRED]

Prognosis following Postanoxic Myoclonus Status epilepticus

Trimethoprim-Sulfamethoxazole Exacerbates Posthypoxic Action Myoclonus in a Patient with Suspicion of Pneumocystis jiroveci Infection

Contact Info

Product

Resources

About